JP2005298522A5 - - Google Patents

Download PDF

Info

Publication number
JP2005298522A5
JP2005298522A5 JP2005188527A JP2005188527A JP2005298522A5 JP 2005298522 A5 JP2005298522 A5 JP 2005298522A5 JP 2005188527 A JP2005188527 A JP 2005188527A JP 2005188527 A JP2005188527 A JP 2005188527A JP 2005298522 A5 JP2005298522 A5 JP 2005298522A5
Authority
JP
Japan
Prior art keywords
component
composition
substance
composition according
par
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2005188527A
Other languages
Japanese (ja)
Other versions
JP2005298522A (en
Filing date
Publication date
Application filed filed Critical
Priority to JP2005188527A priority Critical patent/JP2005298522A/en
Priority claimed from JP2005188527A external-priority patent/JP2005298522A/en
Publication of JP2005298522A publication Critical patent/JP2005298522A/en
Publication of JP2005298522A5 publication Critical patent/JP2005298522A5/ja
Pending legal-status Critical Current

Links

Claims (17)

ＰＡＲ−２を活性化させる成分を含むことを特徴とする胃酸分泌抑制用組成物。 A composition for inhibiting gastric acid secretion, comprising a component that activates PAR-2. ＰＡＲ−２を活性化させる成分を含むことを特徴とする消化管粘液分泌促進用組成物。 A composition for promoting gastrointestinal mucus secretion, comprising a component that activates PAR-2. ＰＡＲ−２を活性化させる成分を含むことを特徴とする消化管粘膜保護用組成物。 A composition for protecting the digestive tract mucosa, comprising a component that activates PAR-2. ＰＡＲ−２を活性化させる成分を含むことを特徴とする、消化器系疾患の予防、治療用組成物。 A composition for preventing or treating digestive system diseases, comprising a component that activates PAR-2. 消化器系疾患が、胃潰瘍、十二指腸潰瘍、胃炎、下痢および腸炎から選択される疾患である請求項４記載の組成物。 The composition according to claim 4, wherein the digestive system disease is a disease selected from gastric ulcer, duodenal ulcer, gastritis, diarrhea and enteritis. 成分がペプチドである請求項１〜５いずれか１項記載の組成物。 The composition according to any one of claims 1 to 5, wherein the component is a peptide. 成分がタンパク質である請求項１〜５いずれか１項記載の組成物。 The composition according to any one of claims 1 to 5, wherein the component is a protein. ＰＡＲ−２を活性化させる成分としてSer-Leu-Ile-Gly-Arg-Leu-NHSer-Leu-Ile-Gly-Arg-Leu-NH as a component to activate PAR-2 22 （配列番号１）およびtrans-シンナモイル-Leu-Ile-Gly-Arg-Leu-オルニチン-NH(SEQ ID NO: 1) and trans-cinnamoyl-Leu-Ile-Gly-Arg-Leu-ornithine-NH 22 （配列番号２）から成る群からなる少なくとも１種のペプチドを含むことを特徴とする、下痢または腸炎の予防、治療用組成物。A composition for preventing or treating diarrhea or enteritis, comprising at least one peptide consisting of the group consisting of (SEQ ID NO: 2). ＰＡＲ−２を活性化させる成分としてトリプシンおよびトリプターゼから選択される少なくとも１種のタンパク質を含むことを特徴とする胃酸分泌抑制用組成物。A gastric acid secretion-suppressing composition comprising at least one protein selected from trypsin and tryptase as a component that activates PAR-2. ＰＡＲ−２を活性化させる成分としてトリプシンおよびトリプターゼから選択される少なくとも１種のタンパク質を含むことを特徴とする消化管粘液分泌促進用組成物。A composition for promoting gastrointestinal mucus secretion, comprising at least one protein selected from trypsin and tryptase as a component that activates PAR-2. ＰＡＲ−２を活性化させる成分としてトリプシンおよびトリプターゼから選択される少なくとも１種のタンパク質を含むことを特徴とする消化管粘膜保護用組成物。A composition for protecting the digestive tract mucosa, comprising at least one protein selected from trypsin and tryptase as a component that activates PAR-2. ＰＡＲ−２を活性化させる成分としてトリプシンおよびトリプターゼから選択される少なくとも１種のタンパク質を含むことを特徴とする、胃潰瘍、十二指腸潰瘍、胃炎、下痢または腸炎の予防、治療用組成物。A composition for preventing or treating gastric ulcer, duodenal ulcer, gastritis, diarrhea or enteritis, comprising at least one protein selected from trypsin and tryptase as a component that activates PAR-2. 成分を失活化または分解する物質を阻害する物質を組み合わせる請求項１〜１２いずれか１項記載の組成物。 The composition according to any one of claims 1 to 12, wherein a substance that inhibits a substance that inactivates or decomposes a component is combined. 成分を失活化または分解する物質を阻害する物質を併用する請求項１３記載の組成物。 14. The composition according to claim 13, wherein a substance that inhibits a substance that inactivates or decomposes a component is used in combination. 成分を失活化または分解する物質を阻害する物質を配合する請求項１３記載の組成物。 14. The composition according to claim 13, which contains a substance that inhibits a substance that inactivates or decomposes components. 阻害する物質がペプチダーゼインヒビターである請求項１３〜１５いずれか１項記載の組成物。 The composition according to any one of claims 13 to 15, wherein the inhibitory substance is a peptidase inhibitor. 徐放化製剤、局所適用製剤、薬物放出制御製剤、腸溶性製剤および胃溶性製剤よりなる群から選択されるＤＤＳ製剤とされる請求項１〜１６いずれか１項記載の組成物。 The composition according to any one of claims 1 to 16 , wherein the composition is a DDS preparation selected from the group consisting of sustained release preparations, topical preparations, drug release control preparations, enteric preparations and gastric preparations.
JP2005188527A 2005-06-28 2005-06-28 Preventive and therapeutic composition for digestive disease Pending JP2005298522A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2005188527A JP2005298522A (en) 2005-06-28 2005-06-28 Preventive and therapeutic composition for digestive disease

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2005188527A JP2005298522A (en) 2005-06-28 2005-06-28 Preventive and therapeutic composition for digestive disease

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2000047515A Division JP4065642B2 (en) 2000-02-24 2000-02-24 Composition for prevention and treatment of digestive system diseases

Publications (2)

Publication Number Publication Date
JP2005298522A JP2005298522A (en) 2005-10-27
JP2005298522A5 true JP2005298522A5 (en) 2007-03-01

Family

ID=35330480

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2005188527A Pending JP2005298522A (en) 2005-06-28 2005-06-28 Preventive and therapeutic composition for digestive disease

Country Status (1)

Country Link
JP (1) JP2005298522A (en)

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5578643A (en) * 1992-05-20 1996-11-26 Loyola University Of Chicago Protective prostaglandins for use in conjunction with chemotherapeutic agents

Similar Documents

Publication Publication Date Title
JPWO2019107530A5 (en)
JP2007526248A5 (en)
JP2021176913A (en) Treatment of osteoporosis
TW200602071A (en) Methods for preventing and treating alzheimer's disease (ad)
DK1739178T3 (en) Delivery of threefold peptides
JP2002523377A5 (en)
WO2000020612A3 (en) Therapeutically active proteins in plants
KR102138390B1 (en) Compounds and methods for inhibiting nhe-mediaded antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
JP2016516428A5 (en)
JP2010500399A5 (en)
SE9800550D0 (en) A pharmaceutical preparation comprising an angiotensin II type 2 receptor agonist, and use thereof
JP2017221201A5 (en)
MXPA05007711A (en) Cop 1 for treatment of inflammatory bowel diseases.
WO2004002445A3 (en) Novel floating dosage form
JP2015509950A5 (en)
JP2006506942A5 (en)
JP2009520758A5 (en)
CA2671949A1 (en) Helicobacter pylori eradicating agent having inhibitory activity on gastric acid secretion
RU2013117758A (en) METHODS AND COMPOSITIONS FOR TREATMENT OF ESOPHAGIA
JP2005517037A5 (en)
JP2006158399A5 (en) Cell growth inhibitory protein and cell growth inhibitor using the same, cancer diagnostic agent and cancer therapeutic agent
CA2400650A1 (en) Compositions for preventing and treating digestive diseases
WO2015113481A1 (en) Oligopeptide molecules, preparation methods therefor and uses thereof
JP2005298522A5 (en)
KR20060083198A (en) Composition for the treatment of a condition requiring inhibition of gastric acid secretion